Comparative efficacy of sodium glucose cotransporter-2 inhibitors in the management of type 2 diabetes mellitus: A real-world experience

Table 1 Baseline clinical and biochemical characteristics of 467 type 2 diabetes mellitus patients treated with sodium glucose cotransporter 2 inhibitors.

Baseline features	n (%) or median (IQR)
Female gender	173 (37.04%)
Age (yr)	64 (14.8)
Ethnicity
British white	338 (72.37%)
Diabetes duration (yr)	16 (9)
Diabetes duration ≥ 10 yr	335 (71.73%)
Years of treatment with SGLT2i	3.6 (2.1)
Body weight (kg)	99 (29)
BMI (kg/m2)	34 (7.58)
BP (mmHg)
Systolic	144 (21)
Diastolic	82 (16)
HbA1c (mmol/mol)	78 (25.5)
Serum creatinine (μmol/L)	74 (21)
eGFR (mL/min/m2)	88.5 (17)
Urine ACR	2.1 (3.95)
GGT	38 (0)
Concomitant medications
Basal-bolus (novorapid + long-acting insulin)	32 (18.7)
Mixed insulin (novomix-30 insulin)	53 (26.4)
Long-acting insulin (lemevir, toujeo, lantus, tresiba, absalgar)	83 (38.1)
Metformin	377 (83.9)
Sulfonylurea (glimepride/glyburide/glipizide)	199 (44.7)
DPP4 inhibitors (sitagliptin, saxagliptin, linagliptin, or alogliptin)	130 (29.1)
Pioglitazone	22 (5)
GLP1 inhibitor (dulaglutide, exanatide, semaglutide, liraglutide)	94 (20.9)

SGLT2i: Sodium glucose cotransporter-2 inhibitor; IQR: Interquartile range; BMI: Body mass index; BP: Blood pressure; HbA1c: Glycated hemoglobin; eGFR: Estimated glomerular filtration rate; ACR: Albumin creatinine ratio; GGT: Gamma glutamyl transpeptidase; DPP4: Dipeptidyl-peptidase 4; GLP1: Glucagon like peptide 1.